11 Jan 2019 Research
Lymphoma: Understanding relapse and treatment resistance
What is this research looking at?
Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.
We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.
We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.
Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.
By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.
We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.
Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.
What could this mean for people with leukaemia?
This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.
Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution
Related posts
15 February 2024
Vogue model who survived leukaemia as a child joins Leukaemia UK in calling for more donations for research to stop blood cancer ‘destroying childhoods’
Vogue model Saffron Vadher has joined Leukaemia UK on International Childhood Cancer Day (February 15th) in calling for more research into the blood cancer. Leukaemia is the most common type…
17 October 2022
New campaign launches for the forgotten 500,000 families
Patient groups, charities and clinicians unite to raise awareness of half a million vulnerable people, many of whose lives have never returned to normal after the Covid-19 lockdown. A new…
4 September 2023
Less than 1% of Brits can identify all the most common symptoms of one of the deadliest types of cancer
New research launched today by Leukaemia Care and Leukaemia UK reveals that less than 1% (0.4%) of UK adults can accurately identify the four most common symptoms of leukaemia –…
14 March 2023
Percy & Nell says Pants to Leukaemia with bespoke charity collaboration
Independent clothing brand Percy & Nell has produced a unique range of sweatshirts, t-shirts, beanies and tote bags, with all profits going to Leukaemia UK. The collaboration comes off the…